news – Page 167

Efficacy and Challenges of Targeted Indoor Residual Spraying for Aedes-Borne Virus Prevention: Insights from a Cluster-Randomized Trial

By MedXY 10/25/2025

This study evaluates targeted indoor residual spraying's effectiveness against Aedes-borne diseases and highlights its limitations despite entomologic success.

Cardiology news Respiratory

Early Intervention in Pulmonary Arterial Hypertension: The Promise of Sotatercept in the First Year Post-Diagnosis

By MedXY 10/25/2025

This article reviews a phase 3 trial analyzing sotatercept's efficacy and safety in newly diagnosed pulmonary arterial hypertension patients, highlighting its potential to reduce clinical worsening early in the disease course.

news Oncology

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial

By MedXY 10/25/2025

The SENTIX trial shows that sentinel lymph node biopsy without full pelvic lymphadenectomy is safe in early-stage cervical cancer, potentially reducing surgical morbidity without compromising oncologic outcomes.

news Oncology

Reevaluating Lymph Node Management in Early-Stage Cervical Cancer: Sentinel Biopsy Alone Shows Promise

By MedXY 10/25/2025

A large randomized trial finds sentinel lymph-node biopsy alone is noninferior to lymphadenectomy in early cervical cancer, with fewer complications and comparable survival outcomes.

Internal Medicine news Rheumatology

Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial

By MedXY 10/25/2025

This article reviews a pivotal phase 3 trial demonstrating telitacicept's efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.

Allergy & Immunology Hematology-Oncology news

Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency

By MedXY 10/25/2025

This study demonstrates the long-term effectiveness and safety of autologous gene therapy for treating ADA deficiency, showing sustained immune function and minimal adverse effects over a median follow-up of 7.5 years.

Infectious Diseases news Pediatrics

Mass Azithromycin Administration in Malian Infants Shows No Mortality Benefit: A Large-Scale Randomized Trial

By MedXY 10/25/2025

A large randomized trial in Mali demonstrated that mass azithromycin administration to infants aged 1–11 months did not reduce mortality compared to placebo, challenging previous findings in sub-Saharan Africa.

news Oncology Respiratory

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope

By MedXY 10/25/2025

This article reviews recent clinical trial data showing sevabertinib's efficacy and safety in treating HER2-mutant NSCLC, highlighting its potential to fill an unmet therapeutic gap.

news Oncology Respiratory

Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study

By MedXY 10/25/2025

This phase II study evaluates the effectiveness and safety of afatinib with platinum-based chemotherapy in NSCLC patients resistant to first-line osimertinib, highlighting promising outcomes and manageable toxicity.

news Oncology Respiratory

Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances

By MedXY 10/25/2025

This article reviews the CHRYSALIS-2 cohort A study demonstrating the potential of combined amivantamab and lazertinib therapy in heavily pretreated EGFR-mutant NSCLC patients.

news Oncology Respiratory

Enhanced Survival in EGFR-Mutated NSCLC: The Impact of Combining Osimertinib with Chemotherapy

By MedXY 10/25/2025

This article reviews the latest evidence demonstrating improved overall survival with osimertinib combined with chemotherapy in first-line treatment of EGFR-mutated advanced non-small-cell lung cancer.

news Oncology Urology

Enhancing Survival in Biochemically Recurrent Prostate Cancer: The Promising Role of Enzalutamide

By MedXY 10/25/2025

This review highlights the recent findings from the EMBARK trial demonstrating improved overall survival with enzalutamide combined with leuprolide in high-risk recurrent prostate cancer.

news Oncology Urology

Long-Term Efficacy and Safety of Belzutifan in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: Insights from the 50-Month LITESPARK-004 Phase 2 Study

By MedXY 10/25/2025

Belzutifan demonstrates sustained tumor response and manageable safety over 50 months in patients with von Hippel-Lindau disease-associated renal cell carcinoma, supporting its role as a systemic therapy.

news Otorhinolaryngology Pediatrics

DB-OTO Gene Therapy: A Breakthrough Treatment for OTOF-Related Inherited Deafness in Children

By MedXY 10/24/2025

Regeneron's DB-OTO gene therapy shows promising results in restoring natural hearing in children with profound hearing loss caused by OTOF gene mutations, with 75% achieving significant hearing improvement after a single treatment.

news

创新口服SERD联合依维莫司疗法在晚期ER+ HER2-乳腺癌中显示优越疗效

By MedXY 10/24/2025

罗氏宣布giredestrant联合依维莫司的III期研究结果积极，显著降低之前接受过CDK4/6抑制剂治疗的ER+ HER2-晚期乳腺癌患者的疾病进展风险，且具有良好的安全性和生存趋势。

Nephrology news Rheumatology

FDA Approves Roche’s Obinutuzumab for Lupus Nephritis: Promising Advances in B-cell Targeted Therapy

By MedXY 10/24/2025

The FDA has approved Roche’s obinutuzumab for active lupus nephritis in adults, offering a twice-yearly dosing regimen that achieved nearly 50% complete renal remission in trials, marking a significant advancement in lupus nephritis management.

Hematology-Oncology news Ophthalmology

Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy

By MedXY 10/24/2025

Recent clinical trials report encouraging tumor shrinkage with KRAS G12D inhibitor VS-7375, significant progression-free survival benefit in soft tissue sarcoma with ozekibart, and a novel gene therapy acquisition targeting wet AMD.

Dermatology news Plastic Surgery

Enhancing Surgical Outcomes: Hydrocolloid Dressings vs Petroleum Ointment for Scar Management

By MedXY 10/24/2025

This clinical trial compares the effectiveness and safety of hydrocolloid dressings versus petroleum ointment in post-surgical scar healing, emphasizing patient comfort and cosmetic outcomes.

Dermatology Hematology-Oncology news

T-Cell Receptor Clonotypes as Prognostic Markers in Cutaneous T-Cell Lymphoma: Insights from Next-Generation Sequencing

By MedXY 10/24/2025

This study identifies specific T-cell receptor clonotypes associated with aggressive subtypes and poorer survival in mycosis fungoides and Sézary syndrome, supporting TCR sequencing as a tool for refined risk stratification in cutaneous T-cell lymphoma.

news Oncology

Promising Dual-Antibody Therapy Petosemtamab Shows Remarkable Response in Metastatic Colorectal Cancer

By MedXY 10/24/2025

Mid-phase clinical data reveal petosemtamab combined with FOLFOX/FOLFIRI achieves up to 100% response in first-line left-sided metastatic colorectal cancer, with manageable safety profile and potential to address unmet needs in mCRC treatment.